The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.
COPENHAGEN, Denmark — A new investigational drug has become the first agent to slow disability in patients with nonrelapsing secondary progressive
The results were presented today by Robert Fox, MD, vice chair of research at the Cleveland Clinic's Neurological Institute, Ohio, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2024 between 3.0 and 6.5, no clinical relapses in the previous 24 months, and documented evidence of disability accumulation in the previous 12 months.
Rates of 3-month confirmed disability progression were 32.6% in the tolebrutinib group versus 41.5% with placebo — a 24% risk reduction. In terms of safety, the main concern is liver enzyme elevations, which occurred at greater than three times the upper limit of normal in 4.1% of the tolebrutinib group versus 1.6% in the placebo group.
Multiple Sclerosis MS - Multiple Sclerosis Disability Aminotransferase Ast Liver Enzymes Liver Studies Alt Transaminase Liver Biologic Therapy Biologics Brain Blood-Brain Barrier BBB - Blood Brain Barrier Toxicology Toxicity Poisoning Toxins Patient Safety Tyrosine Kinase Inhibitor Erlotinib Gefitinib Imatinib Su11248 Sunitinib Otolaryngology ENT Specialty
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Biden holds first Cabinet meeting in nearly a year, first lady joins for first timePresident Biden convened a meeting of his Cabinet -- this time with First Lady Jill Biden attending -- for the first time Friday in nearly a year.
Read more »
From Music to Fiction: Tim Booth to Debut His First Novel at Tattered CoverColorado author Carter Wilson will interview musician and debut novelist Tim Booth at the Tattered Cover on September 16.
Read more »
Lecanemab: First drug to slow Alzheimer’s too costly for NHSHealth assessment body NICE says the benefits “are too small to justify the costs”.
Read more »
Book review: Thomas McGuire’s second novel is as lyrical, intelligent and suspenseful as his first“The Curve of Equal Time” features well-drawn characters and precise and lyrical writing.
Read more »
This Timeless Novel Is Coming to TV For the First Time EverJake Hodges is a senior author at Collider who focuses on the latest releases, from broadcast TV to upcoming movies, with expertise in Doctor Who.
Read more »
Carolina Panthers hosted former first-round NFL draft pick for a free agent workoutHis breakout senior year was impressive enough to get him picked in the first-round (22nd overall) of the 2017 NFL draft by the Miami Dolphins.
Read more »